Funding for this research was provided by:
Uppsala University
Article History
Received: 18 February 2022
Accepted: 24 May 2022
First Online: 26 June 2022
Declarations
:
: W. Graf has received a consulting fee from Galderma Ltd. All authors declare that there is no conflict of interest.
: The primary trial and the 10-year follow-up were approved by the institutional ethical review board (2008/066, 2020–01318). The 12-month results were presented as a poster at the ASCRS annual meeting in San Antonio, Texas, USA, 2–6 June 2012.
: Written informed consent was obtained from all patients included in the study.